RPRX Valuation

Royalty Pharma PLC

Add to Watchlist

Advanced Chart

31.950

+0.740(+2.370%)

Overview
Forecast
Valuation

RPRX Relative Valuation

RPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RPRX is overvalued; if below, it's undervalued.

Historical Valuation

Royalty Pharma PLC (RPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.56 is considered Undervalued compared with the five-year average of 10.91. The fair price of Royalty Pharma PLC (RPRX) is between 36.75 to 65.21 according to relative valuation methord. Compared to the current price of 31.95 USD , Royalty Pharma PLC is Undervalued By 13.05%.

Relative Value

Fair Zone

36.75-65.21

Current Price：31.95

13.05%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.97

P/B

Median3y

2.36

Median5y

2.70

19.80

FCF Yield

Median3y

18.10

Median5y

15.83

Competitors Valuation Multiple

The average P/S ratio for RPRX's competitors is 6.93, providing a benchmark for relative valuation. Royalty Pharma PLC Corp (RPRX) exhibits a P/S ratio of 4.75, which is -31.48% above the industry average. Given its robust revenue growth of -0.41%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap